Oncology Pharma Inc. ONPH
Set alert
0.04 USD +0.01 +32.89%
At close · Oct 30
0.03 Day range 0.0479
0.0001 52-week range 0.364
- YTD
- +900.00%
- 1 year
- +19,900.00%
- Open
- 0.04
- Prev close
- 0.0301
- Mkt cap
- 3.29M
- Vol
- 1.18K
- Avg vol
- 15.76K
- EPS
- -0.23
- P/E
- 0.00
More statistics
- Low
- 0.03
- High
- 0.0479
1M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 2 days ago |
| SMA: Bearish | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
News
- Head to Head Comparison: Oncology Pharma (OTCMKTS:ONPH) & Rafael (NYSE:RFL)
- Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
- Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
- Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
- Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
- Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
- Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
- Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
- Shares of This Biotech Stock Could Jump 437%
- Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
Your note
Sign in to keep a note on ONPH — it syncs with the Stock Master app.